Why Quality Problems Keep Repeating in Medical Device Organizations

Every medical device organization wants to produce safe, effective products while satisfying increasingly rigorous regulatory expectations. Yet many companies continue to experience the same quality problems repeatedly. CAPAs recur. Design reviews uncover familiar deficiencies. FDA observations identify issues that leadership believed had already been resolved. Despite extensive procedures, documented quality systems, and recurring training, execution often remains inconsistent.

This disconnect illustrates one of the most persistent challenges within the industry: understanding quality requirements is not the same as implementing them effectively. Regulations define expectations, and quality systems establish structure, yet sustainable performance ultimately depends on whether engineers, quality professionals, regulatory specialists, and organizational leaders possess the capability to apply those principles consistently in real development environments. Until organizations close the gap between knowledge and execution, quality problems tend to reappear in different forms, consuming valuable time, increasing organizational risk, and delaying innovation.

A thoughtful examination of this issue appears in @McKinsey & Company's paper, "The Business Case for Medical Device Quality," authored by @Ted-Fuhr, @Katy-George, and @Janice-Pai. The authors argue that quality should no longer be viewed solely as a regulatory obligation. Instead, it represents a strategic business capability that directly influences organizational performance, financial outcomes, patient safety, and long-term competitiveness.

The paper explains that increasing product complexity, global supply chains, and heightened regulatory scrutiny have dramatically increased the cost of poor quality. Quality failures now extend far beyond inspection findings or warning letters. They may result in recalls, remediation projects, operational disruption, reputational damage, and significant financial consequences. As the authors note, organizations that consistently outperform their peers are those that integrate quality throughout product design, development, manufacturing, and commercialization rather than treating it as a downstream compliance function.

McKinsey's conclusion is both practical and compelling: organizations should build quality into every phase of the product lifecycle rather than relying on inspection and corrective action after problems emerge. Mature quality systems, integrated operational processes, and a culture that values proactive quality management ultimately reduces costs while improving both business performance and patient outcomes.

I agree with the central premise of the paper. Building quality into the development process is unquestionably more effective than attempting to ‘test’ quality into a finished product. Where I believe many organizations continue to struggle, however, is in understanding what must change for that objective to become reality.

Too often, implementation efforts focus primarily on documentation, procedures, and compliance activities. Those elements are essential, yet they rarely address the underlying reason execution breaks down. Organizations frequently assume that updating procedures, introducing new templates, or delivering additional training will naturally produce better implementation. In practice, the same execution gaps often remain because capability itself has not improved.

Implementation capability is something different. It reflects an organization's ability to translate regulatory expectations into consistent engineering decisions, effective design reviews, meaningful risk management activities, disciplined verification and validation practices, and productive cross-functional collaboration throughout the product lifecycle. It is developed through structured experience, practical application, repeated reinforcement, and an organizational commitment to improving how work is actually performed.

This distinction becomes especially apparent during FDA inspections and remediation projects. Most deficiencies do not arise because professionals were unaware of the regulations. Rather, they occur because implementation gradually drifted away from the original intent of the quality system. Documentation may appear complete while underlying development decisions remain suspect. Procedures may satisfy formal requirements while everyday execution lacks discipline. These situations reveal implementation gaps rather than knowledge gaps.

For leaders responsible for quality, engineering, and product development, this represents an important shift in perspective. The objective should not simply be to strengthen compliance programs. It should be to develop stronger implementation capability throughout the organization. When individuals understand not only what the regulations require, but also how those requirements should guide daily engineering activity, quality systems become more resilient, product development becomes more efficient, and regulatory compliance becomes a natural outcome of disciplined execution rather than the primary objective itself.

The medical device industry does not need more information. It needs stronger implementation.

John Salvato, PhD - Founder & President, Design Quality Services